Skip to main content
SpringerLink
Log in

Targeting and internalization of sterically stabilized liposome modified with ZCH-4-2E8

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

An Erratum to this article was published on 29 December 2009

Summary

Sterically stabilized liposome (SL) modified with 2E8 monoclonal antibody (2E8-SL) was prepared in order to evaluate its targeting ability and internalization efficiency against tumor cells with high expression of CD19. 2E8 was coupled to the surface of SL using post-insertion technique. The shape of liposomes was observed under a transmission electronic microscope. The average size of liposomes was determined by using the Zetasizer instrument. The binding and internalization of 2E8-SL against tumor cells with higher expression of CD19 were tested by flow cytometry and confocal microscopy. The mean diameter of 2E8-SL was 121.25 nm. 2E8-SL was stable after up to 24 days in various buffers. 2E8-SL showed specific binding to tumor cells with high expression of CD19, including B cells in peripheral blood mononuclear cells (PBMCs). 2E8-SL could efficiently internalize into Nalm6 cells with CD19 high expression. It is suggested that 2E8-SL may serve as useful delivery carrier of anti-cancer drugs targeting to hematological malignant tumors with CD19 high expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Current Drug Delivery, 2005, 2(4):369–381

    Article  PubMed  CAS  Google Scholar 

  2. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer, 2002, 2(10):750–763

    Article  PubMed  CAS  Google Scholar 

  3. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J, 2007, 9(2):128–147

    Article  Google Scholar 

  4. Uckun FM, Jaszcz W, Ambrus JL, et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood, 1988, 71(1):13–29

    PubMed  CAS  Google Scholar 

  5. Kong Y, Yoshida S, Saito Y, et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia, 2008, 22(6):1207–1213

    Article  PubMed  CAS  Google Scholar 

  6. Lopes D, Menezes DE. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma Cell, J Liposome Res, 1999, 9(2):199–228

    Article  Google Scholar 

  7. Pastorino F, Brignole C, Marimpietri D, et al. Doxorubicin-loaded Fab’ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res, 2003, 63(1):86–92

    PubMed  CAS  Google Scholar 

  8. Sapra P, Moase EH, Ma J. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab’ fragments. Clin Cancer Res, 2004, 10(3):1100–1111

    Article  PubMed  CAS  Google Scholar 

  9. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res, 2002, 62(24):7190–7194

    PubMed  CAS  Google Scholar 

  10. Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res, 2004, 10(7):2530–2537

    Article  PubMed  CAS  Google Scholar 

  11. Tang YM, Guo SF. The preparation and application of ZCH-4-2E8: a monoclonal antibody specific targeting to B lymphocyte. J Zhejiang Med Univ (Chinese), 1994, 23(6):246–248

    CAS  Google Scholar 

  12. Li LX, Tang YM, Zhang HZ, et al. Preparation of the immunotoxin 2E8-norcantharidin and its targeting killing effect in vitro. Zhonghua Er Ke Za Zhi (Chinese), 2008, 46(7):493–497

    Google Scholar 

  13. Wu JM, Ren TC. The preparation of characters of liposome containing norcnatharidin, Chin Phar J, 2001, 19(40):1485–1487

    Google Scholar 

  14. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta, 2001, 1513(2):207–216

    Article  PubMed  CAS  Google Scholar 

  15. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004, 351(4):337–345

    Article  PubMed  CAS  Google Scholar 

  16. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol, 2005, 23(15):3502–3508

    Article  PubMed  CAS  Google Scholar 

  17. Zhou Y, Drummond DC, Zou H, et al. Impact of Single-chain Fv antibody fragment affinity on Nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol, 2007, 371(4):934–947

    Article  PubMed  CAS  Google Scholar 

  18. Yang T, Choi MK, Cui FD, et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release, 2007, 120(3):169–177

    Article  PubMed  CAS  Google Scholar 

  19. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma, 1998, 58(15):3320–3330

    CAS  Google Scholar 

  20. Asai T, Shimizu K, Kondo M, et al. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett, 2002, 520(1–3):167–170

    Article  PubMed  CAS  Google Scholar 

  21. Gabizon A, Horowitz AT, Goren D, et al. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res, 2003, 9(17):6551–6559

    PubMed  CAS  Google Scholar 

  22. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res, 2003, 42(5):439–462

    Article  PubMed  CAS  Google Scholar 

  23. Lu J, Jeon E, Lee BS, et al. Targeted drug delivery crossing cytoplasmic membranes of intended cells via ligand-grafted sterically stabilized liposomes. J Control Release, 2006, 110(3):505–513

    Article  PubMed  CAS  Google Scholar 

  24. Pan H, Niu GQ, Pan J, Lu WY. Preparation and in vitro targeting of sterically stabilized liposomes modified with chimeric TNT-3 monoclonal antibody. Yao Xue Xue Bao (Chinese), 2006, 41(6):506–512

    CAS  Google Scholar 

  25. Cheng WW, Das D, Suresh M, et al. Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim Biophys Acta, 2007, 1768(1):21–29

    Article  PubMed  CAS  Google Scholar 

  26. Lopes de Menezes DE, Pilarski LM, et al. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta, 2002, 1466(1–2):205–220

    Google Scholar 

  27. Harata M, Soda Y, Tani K, et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood, 2004, 104(5):1442–1449

    Article  PubMed  CAS  Google Scholar 

  28. Luque R, Brieva JA, Moreno A, et al. Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients—diagnostic and clinical implications. Clin Exp Immunol, 1998, 112(3):410–418

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology-Oncology, Children’ Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China

    Jingying Zhang  (张晶樱), Yongmin Tang  (汤永民), Hongqiang Shen  (沈红强) & Baiqin Qian  (钱柏芹)

Authors
  1. Jingying Zhang  (张晶樱)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongmin Tang  (汤永民)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongqiang Shen  (沈红强)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Baiqin Qian  (钱柏芹)
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This Project was supported by the National Basic Research Program of China (No. Z205166).

An erratum to this article is available at http://dx.doi.org/10.1007/s11596-009-0626-y.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, J., Tang, Y., Shen, H. et al. Targeting and internalization of sterically stabilized liposome modified with ZCH-4-2E8. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 29, 273–280 (2009). https://doi.org/10.1007/s11596-009-0302-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-009-0302-2

Key words

Search

Navigation